Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metaproterenol + theophylline
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Inhalation
01
Overview
A combination bronchodilator medication containing metaproterenol and theophylline used to treat chronic airflow obstruction (CAO), asthma, and other lung diseases. Metaproterenol provides rapid bronchodilation while theophylline offers sustained bronchodilator effects. The combination works by relaxing the smooth muscles in the bronchial tubes and increasing airflow through the lungs.
02
Targets
ADOR (Adenosine receptors)PDE (Phosphodiesterase family)HDAC (HDAC family)
Beyond the preview
Go deeper on metaproterenol + theophylline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metaproterenol + theophylline.